Trial · NCT00462020
Intravenous Versus Intravenous/Oral Antibiotics for Perforated Appendicitis
NCT00462020, Not applicable, Completed, Children's Mercy Hospital Kansas City; results first posted 2011-12-13
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Intravenous Versus Intravenous/Oral Antibiotics for Perforated Appendicitis. Trials, record NCT00462020. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00462020
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Intravenous Versus Intravenous/Oral Antibiotics for Perforated Appendicitis
- NCT number
- NCT00462020
- Status
- Completed
- Phases
- Not applicable
- Enrollment
- 102 participants, actual
- Lead sponsor
- Children's Mercy Hospital Kansas City
- Conditions
- Perforated Appendicitis
- Interventions
- 5 days of IV antibiotics (ceftriaxone and metronidazole), Home with oral antibiotics when eating (ampicillin/clavulanic acid)
- First posted
- 2007-04-18
- Last updated
- 2021-02-21
- Results first posted
- 2011-12-13
Source ClinicalTrials.gov
Registered outcomes5
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Abscess After Appendectomy | 1 month | |
| Secondary | Operative Time | 1 month | |
| Secondary | Time to Regular Diet | 1 month | |
| Secondary | Length of Stay After Operation | 1 month | |
| Secondary | Total Healthcare Visits | 1 month |
Source ClinicalTrials.gov
Outcomes5
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Abscess After Appendectomy | 1 month | number of patients | NUMBER | |
| SECONDARY | Operative Time | 1 month | Minutes | MEAN | |
| SECONDARY | Time to Regular Diet | 1 month | Hours | MEAN | |
| SECONDARY | Length of Stay After Operation | 1 month | Days | MEAN | |
| SECONDARY | Total Healthcare Visits | 1 month | Visits | MEAN |
Source ClinicalTrials.gov
Results by group10
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Abscess After Appendectomy | IV Only | 10 | number of patients | ||
| Abscess After Appendectomy | IV and Oral Abx | 10 | number of patients | ||
| Operative Time | IV Only | 41.06 | Standard Deviation 15.36 | Minutes | |
| Operative Time | IV and Oral Abx | 46.30 | Standard Deviation 19.42 | Minutes | |
| Time to Regular Diet | IV Only | 68.00 | Standard Deviation 35.06 | Hours | |
| Time to Regular Diet | IV and Oral Abx | 61.42 | Standard Deviation 32.12 | Hours | |
| Length of Stay After Operation | IV Only | 6.06 | Standard Deviation 2.00 | Days | |
| Length of Stay After Operation | IV and Oral Abx | 4.48 | Standard Deviation 2.36 | Days | |
| Total Healthcare Visits | IV Only | 3.1 | Standard Deviation 1.4 | Visits | |
| Total Healthcare Visits | IV and Oral Abx | 3.1 | Standard Deviation 1.2 | Visits |
Source ClinicalTrials.gov
Participant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | IV Only | 52 | |
| Overall Study | STARTED | IV and Oral Abx | 50 | |
| Overall Study | COMPLETED | IV Only | 52 | |
| Overall Study | COMPLETED | IV and Oral Abx | 50 | |
| Overall Study | NOT COMPLETED | IV Only | 0 | |
| Overall Study | NOT COMPLETED | IV and Oral Abx | 0 |
Source ClinicalTrials.gov
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | IV Only | 0 | 52 |
| Total, all-cause mortality | IV and Oral Abx | 0 | 50 |
| Total, other adverse events | IV Only | 0 | 52 |
| Total, other adverse events | IV and Oral Abx | 0 | 50 |
| Total, serious adverse events | IV Only | 0 | 52 |
| Total, serious adverse events | IV and Oral Abx | 0 | 50 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons2
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|---|
| IV Only vs IV and Oral Abx: deaths from any cause | Trial comparisons |
| IV Only vs IV and Oral Abx: serious adverse events | Trial comparisons |
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00462020
GET https://conductscience.org/api/trials/v1/NCT00462020/registered